Australia's Noxopharm rises chemotherapy patent in Australia, Europe

Noxopharm

25/10/2021 05:40

** Drug developer Noxopharm Ltd  NOX.AX  rises as much as
4.7% to A$0.560
    ** Says it received patents from Australian and European
patent offices for usage of idronoxil as a chemo-enhancing drug
 urn:newsml:reuters.com:*:nASXb86DFv
    ** Drug Veyonda, which contains idronoxil, allows dosages of
chemotherapy to be lowered without risking its anti-cancer
effectiveness
    ** Pre-clinically, idronoxil increases cancer killing effect
of all common chemotherapies up to magnitudes exceeding
1,000-times - NOX
    ** More than 272,000 shares traded vs their 30-day average
of about 249,000 shares
    ** NOX up 9.2% this year, as of last close

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com))